Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
- Conditions
- Lymphoma
- Registration Number
- NCT01131208
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Brief Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in patients with diffuse large B-cell lymphoma treated with combination chemotherapy with or without rituximab.
- Detailed Description
OBJECTIVES:
* To identify genes predictive of clinical outcome (failure-free survival and overall survival) among patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP induction on ECOG-E4494 using the nuclease protection assay for measuring gene expression in paraffin-embedded tissue.
* To identify genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy.
OUTLINE: This is a multicenter study.
Unstained formalin-fixed, paraffin-embedded samples are analyzed for gene expression via nuclease protection assay.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of genes predictive of clinical outcome 1 month Identification of genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy 1 month
- Secondary Outcome Measures
Name Time Method